Skip to main content
NCBI home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2000 Aug;15(Suppl 1):101–109. doi: 10.1007/BF02867549

Clinical and oncological significance of aberrant Fas (APO-1/CD95) isoform expression in adult T-cell leukemia

Shimeru Kamihira 1,✉, Yasuaki Yamada 1, Takahiro Maeda 1
PMCID: PMC3454065  PMID: 23105273

Abstract

Fas (APO-1/CD95), a transmembrane death receptor mediating apoptosis, can induce cell deathin vivo andin vitro of not only normal T-cells but also leukemic T-cells. This indicates that dysfunction in T-cell apoptosis may influence the natural history of the T-cell neoplasms, such as adult T-cell leukemia (ATL) caused by the retrovirus HTLV-1. Fas is ubiquitous, and down-regulated or mutated Fas has been widely detected in tumor cells that escape from elimination via Fas-mediated apoptosis. De novo fresh ATL cells and cell lines derived from the de novo cells, however, express Fas abundantly on the cell surface and are susceptible to Fas ligand and agonistic agents. On the other hand, there are two types of Fas gene transcripts, full-length and alternatively splicing truncated forms corresponding to membrane and soluble Fas isoforms, respectively. Focusing on membrane and soluble Fas isoforms and ATL pathology mediated by apoptosis, this paper reviews and discusses our ATL cases and ATL cell lines, which provide useful “experiments of nature” for understanding the role of Fas-mediated apoptosis in tumor biology.

Key Words: Fas (APO-1/CD95), apoptosis, mutation, ATL, HTLV-1

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

References

  • 1.Yonehara S., Ishii A., Yonehara M. A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down regulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989;169:1747–1756. doi: 10.1084/jem.169.5.1747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233–243. doi: 10.1016/0092-8674(91)90614-5. [DOI] [PubMed] [Google Scholar]
  • 3.Trauth B.C., Klas C., Peters A.M.J., Matzku S., Moller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science. 1989;245:301–305. doi: 10.1126/science.2787530. [DOI] [PubMed] [Google Scholar]
  • 4.Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169–1178. doi: 10.1016/0092-8674(93)90326-L. [DOI] [PubMed] [Google Scholar]
  • 5.Ogasawara J., Suda T., Nagata S. Selective apoptosis of CD4+ CD8+ thymocytes by the anti-Fas antibody. J. Exp. Med. 1995;181:485–491. doi: 10.1084/jem.181.2.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorders in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314–317. doi: 10.1038/356314a0. [DOI] [PubMed] [Google Scholar]
  • 7.Ju S.T., Panka D.J., Cui H., Effinger R., Ei Khatib M., Sherr D.H., Stanger B.Z., Marshak-Rothstein A. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444–448. doi: 10.1038/373444a0. [DOI] [PubMed] [Google Scholar]
  • 8.Nagata S., Goldstein P. The Fas death Factor. Science. 1995;267:1449–1456. doi: 10.1126/science.7533326. [DOI] [PubMed] [Google Scholar]
  • 9.Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.P. Protein from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759–1762. doi: 10.1126/science.7510905. [DOI] [PubMed] [Google Scholar]
  • 10.Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., Ruberiti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol. 1996;156:4622–4630. [PubMed] [Google Scholar]
  • 11.Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 1992;89:4845–4849. doi: 10.1073/pnas.89.11.4845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Heaney M.L., Goldem D.W. Soluble Cytokine receptors. Blood. 1996;87:847–857. [PubMed] [Google Scholar]
  • 13.Rieux-Laucat F., Deist F., Hivroz C., Roberts I.A.G., Debatin K.M., Fischer A., DeVillartay J.P. Mutations in Fas as associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347–1349. doi: 10.1126/science.7539157. [DOI] [PubMed] [Google Scholar]
  • 14.Adachi M., Watanabe-Fukunaga R., Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an insortion of the Fas antigen gene of lpr mice. Proc Natl. Acad. Sci. 1993;90:1756–1760. doi: 10.1073/pnas.90.5.1756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Beltinger C., Kurz E., Bohler T., Schrappe M., Ludwig W.D., Debatin K.M. CD95(Apo-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91:3943–3951. [PubMed] [Google Scholar]
  • 16.Landowski T., Qu N., Buyuksal I., Painter J.S., Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 1997;90:4266–4270. [PubMed] [Google Scholar]
  • 17.Tamiya S., Etoh K., Suzushima H., Takatsuki K., Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 1998;91:3935–3942. [PubMed] [Google Scholar]
  • 18.Reyher U., Strater J., Kittstein W., Gschwendt M., Krammer P.H., Moller P. Colon Carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 1998;58:526–534. [PubMed] [Google Scholar]
  • 19.Leithauser F., Dhein J., Mechtersheimer G., Korets K., Bruderlein S., Henne C., Schmidt A., Debatin K.M., Krammer P.H., Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab. Invest. 1993;69:415–429. [PubMed] [Google Scholar]
  • 20.Sugahara K., Yamada Y., Hirakata Y., Matsuda Y., Tsuruda K., Tomonaga M., Maeda T., Atogami S., Tsukasaki K., Kamihira S. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines. Int. J. Cancer. 1997;72:128–132. doi: 10.1002/(SICI)1097-0215(19970703)72:1<128::AID-IJC18>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  • 21.Tachibana O., Nakazawa H., Lampe J., Watanabe K., Kleihues P., Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 1995;55:5528–5530. [PubMed] [Google Scholar]
  • 22.Seiki M., Hikikoshi S., Taniguchi T., Yoshida M. Expression of the pX gene of HTLV-1; General splicing mechanism in the HTLV-1 family. Science. 1985;228:1532–1534. doi: 10.1126/science.2990031. [DOI] [PubMed] [Google Scholar]
  • 23.Yoshida M., Suzuki T. Regulation of HTLV-1 gene expression and its roles in ATL development. In: Takatsuki K., editor. Adult T-cell leukemia. UK, Oxford: Oxford press; 1994. pp. 28–28. [Google Scholar]
  • 24.Debatin K.M., Goldman C.K., Waldmann T.A., Krammer P.H. APO-1 induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood. 1993;81:2972–2977. [PubMed] [Google Scholar]
  • 25.Kamihira S., Yamada Y., Hirakata Y., Tsuruda K., Sugahara K., Tomonaga M., Maeda T., Tsukasaki K., Atogami S., Kobayashi N. Quantitative Characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukemic cells from chronic B and T lymphoid leukemias. Brit. J. Haematol. 1997;99:858–865. doi: 10.1046/j.1365-2141.1997.4963301.x. [DOI] [PubMed] [Google Scholar]
  • 26.Kamihira S., Yamada Y., Tomonaga M., Sugahara K., Tsuruda K. Discrepant expression of membrane and soluble isoforms of Fas (CD95/Apo-1) in adult T-cell leukemia: soluble Fas isoform is an independent risk factor for prognosis. Brit. J. Haematol. 1997;107:851–860. doi: 10.1046/j.1365-2141.1999.01792.x. [DOI] [PubMed] [Google Scholar]
  • 27.Maeda T., Yamada Y., Moriuchi R., Sugahara K., Tsuruda K., Joh T., Atogami S., Tsukasaki K., Tomonaga M., Kamihira S. Fas gene mutation in the progression of adult T-cell leukemia. J. Exp. Med. 1999;189:1063–1071. doi: 10.1084/jem.189.7.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Natali G., Costanzo A., Petrillo G., Ilari I., Chirillo P., Balsano C., Levrero M. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene. 1995;21:1157–1164. [PubMed] [Google Scholar]
  • 29.Beletskais I.V., Nazarova L.F., Nikonova L.V., Abbasova E.G., Beletskii I.P. Cell sensitivity to Fas-mediated apoptosis dependeds on three forms of Fas-antigen. Izv. Akad. Nauk Ser Biol. 1998;2:187–193. [PubMed] [Google Scholar]
  • 30.Tsuruda K., Yamada Y., Hirakata Y., Sugahara K., Maeda K., Atogami S., Tomonaga M., Kamihira S. Quantitative and qualitative characterization of Fas(APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms. Leukemia Res. 1999;23:159–166. doi: 10.1016/S0145-2126(98)00158-1. [DOI] [PubMed] [Google Scholar]
  • 31.Rieux-Laucat F., Blachere S., Danielan S., Villartary J.P., Oleastro M., Solary E., Bader-Meunier B., Arkwright P., Pondare C., Bernaudin F., Chapel H., Nielsen S., Berrah M., Fisher A., Deist F. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestation. Blood. 1999;94:2575–2582. [PubMed] [Google Scholar]
  • 32.Drappa J.K., Vaishaw A.E., Sullivan K., Chu J-L.B., Elkon K. Fas gene mutation in the Canale-Smith syndrome with autoimmunity. New Engl. J. Med. 1996;335:1643–1649. doi: 10.1056/NEJM199611283352204. [DOI] [PubMed] [Google Scholar]
  • 33.Casino I., Papoff G., Maria R., Testi R., Ruberti G. Fas/Apo-1(CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 1996;156:13–17. [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES